Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst
Novo Nordisk shares rose 4.3% to 389.95 Danish crowns in Copenhagen by 1318 CET Thursday, recovering most of Wednesday’s 4% drop. The move follows an expanded diabetes cell-therapy partnership with Aspect Biosystems announced this week. Investors are awaiting Novo’s full-year results on Feb. 4 for further guidance.